Scinovex
Subscribe
J

Jonathan A. Ledermann

CRUK Lung Cancer Centre of ExcellenceORCID https://orcid.org/0000-0003-3799-3539
h-index
—
Publications
—
Citations
—
i10-index
—
Impact (2-yr)
—

Top Publications

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology20171,842 citations
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology20171,842 citations
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
The Lancet Oncology20141,433 citationsFirst authorCorresponding
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Annals of Oncology20151,359 citations
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Annals of Oncology20151,359 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology20191,130 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology20191,130 citations
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology20131,110 citationsFirst authorCorresponding